Investment analysts at B. Riley began coverage on shares of Asterias Biotherapeutics (NYSEAMERICAN:AST) in a research report issued on Thursday. The brokerage set a “buy” rating and a $6.00 price target on the biotechnology company’s stock. B. Riley’s target price would indicate a potential upside of 192.68% from the company’s current price.
AST has been the topic of a number of other research reports. Zacks Investment Research downgraded Asterias Biotherapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, November 22nd. HC Wainwright set a $11.00 target price on Asterias Biotherapeutics and gave the company a “buy” rating in a research report on Monday, January 8th. Two equities research analysts have rated the stock with a sell rating and four have given a buy rating to the stock. Asterias Biotherapeutics currently has a consensus rating of “Hold” and an average price target of $8.35.
Shares of Asterias Biotherapeutics (NYSEAMERICAN:AST) opened at $2.05 on Thursday. Asterias Biotherapeutics has a 1 year low of $1.95 and a 1 year high of $4.30. The company has a market capitalization of $111.01, a price-to-earnings ratio of -3.15 and a beta of 1.07.
COPYRIGHT VIOLATION WARNING: “Asterias Biotherapeutics (AST) Coverage Initiated by Analysts at B. Riley” was first posted by Week Herald and is the property of of Week Herald. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright & trademark law. The original version of this story can be accessed at https://weekherald.com/2018/02/22/asterias-biotherapeutics-ast-coverage-initiated-by-analysts-at-b-riley.html.
Asterias Biotherapeutics Company Profile
Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.
Receive News & Ratings for Asterias Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.